These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

191 related items for PubMed ID: 2952810

  • 1. Metastatic cancer of the prostate managed with buserelin versus buserelin plus cyproterone acetate.
    Schroeder FH, Lock TM, Chadha DR, Debruyne FM, Karthaus HF, de Jong FH, Klijn JG, Matroos AW, de Voogt HJ.
    J Urol; 1987 May; 137(5):912-8. PubMed ID: 2952810
    [Abstract] [Full Text] [Related]

  • 2. Influence of different types of antiandrogens on luteinizing hormone-releasing hormone analogue-induced testosterone surge in patients with metastatic carcinoma of the prostate.
    Schulze H, Senge T.
    J Urol; 1990 Oct; 144(4):934-41. PubMed ID: 2144596
    [Abstract] [Full Text] [Related]

  • 3. Cyproterone acetate lead-in prevents initial rise of serum testosterone induced by luteinizing hormone-releasing hormone analogs in the treatment of metastatic carcinoma of the prostate.
    Boccon-Gibod L, Laudat MH, Dugue MA, Steg A.
    Eur Urol; 1986 Oct; 12(6):400-2. PubMed ID: 2949980
    [Abstract] [Full Text] [Related]

  • 4. Results of a Dutch trial with the LHRH agonist buserelin in patients with metastatic prostatic cancer and results of EORTC studies in prostatic cancer.
    Debruyne FM.
    Am J Clin Oncol; 1988 Oct; 11 Suppl 1():S33-5. PubMed ID: 2968760
    [Abstract] [Full Text] [Related]

  • 5. Rat prostatic weight regression in reaction to ketoconazole, cyproterone acetate, and RU 23908 as adjuncts to a depot formulation of gonadotropin-releasing hormone analogue.
    Lamberts SW, Uitterlinden P, de Jong FH.
    Cancer Res; 1988 Nov 01; 48(21):6063-8. PubMed ID: 2844399
    [Abstract] [Full Text] [Related]

  • 6. Treatment of prostatic cancer by monthly injections of an LHRH-analogue depot.
    Hjertberg H, Varenhorst E, Svensson M, Kågedal B, Nordenskjöld B.
    Acta Oncol; 1988 Nov 01; 27(4):361-4. PubMed ID: 2974290
    [Abstract] [Full Text] [Related]

  • 7. The effect of previous endocrine therapy on responses to a single dose of an LHRH analogue.
    Allen JM, Williams G, O'Shea JP, Smith C, Yeo T, Kerle D, Bloom SR.
    Urol Res; 1984 Nov 01; 12(5):249-51. PubMed ID: 6240150
    [Abstract] [Full Text] [Related]

  • 8. Zoladex vs. Zoladex plus cyproterone acetate in the treatment of advanced prostatic cancer: a multicenter Italian study.
    Di Silverio F, Serio M, D'Eramo G, Sciarra F.
    Eur Urol; 1990 Nov 01; 18 Suppl 3():54-61. PubMed ID: 2151278
    [Abstract] [Full Text] [Related]

  • 9. Orchidectomy versus Buserelin in combination with cyproterone acetate, for 2 weeks or continuously, in the treatment of metastatic prostatic cancer. Preliminary results of EORTC-trial 30843.
    de Voogt HJ, Klijn JG, Studer U, Schröder F, Sylvester R, De Pauw M.
    J Steroid Biochem Mol Biol; 1990 Dec 20; 37(6):965-9. PubMed ID: 2149509
    [Abstract] [Full Text] [Related]

  • 10. The clinical and endocrine assessment of three different antiandrogen regimens combined with a very long-acting gonadotrophin-releasing hormone analogue.
    Waxman J, Williams G, Sandow J, Hewitt G, Abel P, Farah N, Fleming J, Cox J, O'Donoghue EP, Sikora K.
    Am J Clin Oncol; 1988 Dec 20; 11 Suppl 2():S152-5. PubMed ID: 2853934
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Treatment of locally advanced prostatic carcinoma with LHRH analogues: cytological, DNA-cytophotometrical, and clinical results.
    Borgmann V, al-Abadi H, Nagel R.
    Am J Clin Oncol; 1988 Dec 20; 11 Suppl 1():S19-28. PubMed ID: 2968759
    [Abstract] [Full Text] [Related]

  • 14. Effects of cyproterone acetate and a long-acting LHRH analogue on serum lipoproteins in patients with carcinoma of the prostate.
    Paisey RB, Kadow C, Bolton C, Hartog M, Gingell JC.
    J R Soc Med; 1986 Apr 20; 79(4):210-1. PubMed ID: 2939240
    [Abstract] [Full Text] [Related]

  • 15. Short-term versus long-term addition of cyproterone acetate to buserelin therapy in comparison with orchidectomy in the treatment of metastatic prostate cancer. European Organization for Research and Treatment of Cancer--Genitourinary Group.
    Klijn JG, de Voogt HJ, Studer UE, Schröder FH, Sylvester R, De Pauw M.
    Cancer; 1993 Dec 15; 72(12 Suppl):3858-62. PubMed ID: 8252504
    [Abstract] [Full Text] [Related]

  • 16. Treatment of benign prostatic hyperplasia by androgen deprivation: effects on prostate size and urodynamic parameters.
    Bosch RJ, Griffiths DJ, Blom JH, Schroeder FH.
    J Urol; 1989 Jan 15; 141(1):68-72. PubMed ID: 2462067
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Advanced prostatic cancer: clinical and hormonal response to flutamide in patients pretreated with LHRH analogue and cyproterone acetate.
    Di Silverio F, Sciarra F, D'Eramo G.
    Eur Urol; 1990 Jan 15; 18(1):10-5. PubMed ID: 2144819
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.